Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
British Journal of Clinical Pharmacology|January 25, 2019
Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney diseaseMatthew Sheetz, Philip Barrington, Sophie Callies, et al.
Clinical Pharmacokinetics|March 27, 2025
Pharmacokinetics and Safety of Navitoclax in Hepatic ImpairmentMaulik Patel, Jalaja Potluri, Thomas Marbury, et al.
British Journal of Clinical Pharmacology|December 20, 2019
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatinPratik Bhagunde, Francheska Colon-Gonzalez, Yang Liu, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2012
Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteersJarasvech Chinsangaram, Kady M Honeychurch, Shanthakumar R Tyavanagimatt, et al.
The Journal of Infectious Diseases|May 1, 2008
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjectsMary K Wloch, Larry R Smith, Souphaphone Boutsaboualoy, et al.
European Journal of Drug Metabolism and Pharmacokinetics|December 17, 2017
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic ImpairmentWilliam L Marshall, Hwa-Ping Feng, Larissa Wenning, et al.
Antiviral Therapy|August 9, 2014
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis CEric Lawitz, Daniel Gruener, Thomas Marbury, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
Nature|March 11, 2015
Clinical improvement in psoriasis with specific targeting of interleukin-23Tamara Kopp, Elisabeth Riedl, Christine Bangert, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2012
Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteersJarasvech Chinsangaram, Kady M Honeychurch, Shanthakumar R Tyavanagimatt, et al.
Pageof 8